

Tsingtao Brewery (168 HK)

2Q rev/np +8%/14% on recurring strengths

Tsingtao reported 14% growth in 2Q net profits to RMB2.0bn. Driven by 3% volume growth and 5% ASP uptick, revenue stood at RMB11bn, up 8% YoY. This compared to HSD growth of CR Beer and 20% of Budweiser. Gross/EBIT margins was up approximately 2pp to 33%/21%, respectively, and we expect recurring strengths in both premiumization and cost efficiency to fuel margins expansion into 2H. Specifically, during the analyst call, management commented that they have been taking the initiative to conduct ongoing price reviews. Like-for-like price hikes are unlikely to take place this year, given faltering purchasing power. This is, however, Tsingtao has selectively lifted up prices in the areas where the brand has stronger pricing power, and similar opportunities should exist in 2H. Meanwhile, mix improvement, as another engine of ASP uptick, should prevail and the 15% sub-premium+ shipment growth (including 15% in Classic, 40% in Wheat beer, 20% in Draft etc) in 1H (to 39% of total) should hold through the reminder of the year. On the cost side, management acknowledged that there will be room for raw material cost savings over 2H, and even next year, when they are now able to procure barley from Australia at a lower cost, relative to that from the US at a higher price. These should substantiate our current earnings forecasts and hence our buy call. Among breweries, we still prefer CR Beer (291HK, BUY) and Tsingtao (168HK, BUY) to Budweiser (1876HK, HOLD).

- Call takeaways. 1) Shandong and Eastern China saw faster sales growth, when promotional effort and hence consumer trade-up is bearing fruit. There will be further strategy optimization for these regions in 2H; 2) Capacity optimization has been carrying out pre-COVID, and benefits have started surfacing; 3) Extreme weather has disrupted peak season sales in August, but there could still be opportunities to make up the loss in the festive September; 4) Government subsidy income was partially delayed and decreased by RMB70mn for the quarter and resulted in a lower reported net profits; 5) Management expense was well controlled in 1H (down 0.7pp to 3% of revenue) and the trend should extend into 2H.
- Earnings change. Our 2023E earnings forecasts are largely unchanged.
- Valuation. Our revised TP is based on an unchanged 15.0x end-23E EV/EBITDA which still represents +1sd above long-term average since 2018.

Earnings Summary

(YE 31 Dec)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue (RMB mn)	30,167	32,172	35,702	38,307	40,985
YoY growth (%)	8.7	6.6	11.0	7.3	7.0
Net profit (RMB mn)	3,155.5	3,710.6	4,391.2	4,922.1	5,482.2
YoY growth (%)	43.3	17.6	18.3	12.1	11.4
EPS (RMB)	2.3	2.7	3.2	3.6	4.0
Consensus EPS (RMB)	na	na	3.2	3.7	4.2
P/E (x)	25.4	22.0	19.3	17.2	15.4
P/B (x)	3.5	3.2	3.1	2.9	2.7
Yield (%)	1.9	3.0	3.4	3.9	4.3
ROE (%)	14.5	15.3	16.6	17.3	17.9
Net gearing (%)	Net cash	Net cash	Net cash	Net cash	Net cash
Source: Company data, Bloomb	erg, CMBIGM e	stimates			

BUY (Maintain)

 Target Price
 HK\$88.9

 (Previous TP
 HK\$92.9)

 Up/Downside
 32.9%

 Current Price
 HK\$66.9

China Consumer Staples

Joseph WONG (852) 3900 0838

josephwong@cmbi.com.hk

Bella LI

(852) 3757 6202 bellali@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	91,275.3
Avg 3 mths t/o (HK\$ mn)	189.2
52w High/Low (HK\$)	85.70/55.00
Total Issued Shares (mn)	1364.4
O	

Shareholding Structure

Tsingtao Beer Group Co.	32.5%
China Securities Finance Co.	1.2%

Source: HKEx

Share Performance

	Absolute	Relative
1-mth	-6.9%	2.3%
3-mth	-5.2%	-3.0%
6-mth	-13.6%	-5.7%

Source: FactSet

12-mth Price Performance



Source: FactSet

Related reports:

- 1. <u>CR Beer (291 HK) 1H rev/EBIT +13%/26%; Heineken grew 60%</u> 21 Aug
- 2. Budweiser APAC (1876 HK) 2Q organic sales +15%; overall a mix bag but we see China strength a good trade 4 Aug 2023
- 3. Kweichou Moutai (600519 CH) 20 Rev/NP +20.4/21.0% as pre-announced 3 Aug 2023



Figure 1: Earnings revision

New			Old			Diff (%)			
RMB mn	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	35,702	38,307	40,985	35,852	39,475	43,570	-0.4%	-3.0%	-5.9%
Gross Profit	10,763	11,922	13,133	10,869	12,414	14,170	-1.0%	-4.0%	-7.3%
EBITDA	5,785	6,601	7,456	5,795	6,816	7,967	-0.2%	-3.1%	-6.4%
Net profit	4,391	4,922	5,482	4,398	5,081	5,861	-0.2%	-3.1%	-6.5%
Gross Margin	30.1%	31.1%	32.0%	30.3%	31.4%	32.5%	-0.2ppt	-0.3ppt	-0.5ppt
EBITDA Margin	16.2%	17.2%	18.2%	16.2%	17.3%	18.3%	0ppt	0ppt	-0.1ppt
Net Margin	12.3%	12.8%	13.4%	12.3%	12.9%	13.5%	0ppt	0ppt	-0.1ppt


Source: CMBIGM estimates

Figure 2: CMBIGM estimates vs consensus

СМВІСМ			Consensus			Diff (%)			
RMB mn	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	35,702	38,307	40,985	34,925	37,018	39,126	2.2%	3.5%	4.8%
Gross Profit	10,763	11,922	13,133	13,293	14,601	15,896	-19.0%	-18.3%	-17.4%
EBITDA	5,785	6,601	7,456	6,226	7,237	7,996	-7.1%	-8.8%	-6.7%
Net profit	4,391	4,922	5,482	4,327	4,986	5,580	1.5%	-1.3%	-1.8%
Gross Margin	30.1%	31.1%	32.0%	38.1%	39.4%	40.6%	-7.9ppt	-8.3ppt	-8.6ppt
EBITDA Margin	16.2%	17.2%	18.2%	17.8%	19.5%	20.4%	-1.6ppt	-2.3ppt	-2.2ppt
Net Margin	12.3%	12.8%	13.4%	12.4%	13.5%	14.3%	-0.1ppt	-0.6ppt	-0.9ppt


Source: Bloomberg, CMBIGM estimates

Figure 3: 12M forward EV/EBITDA band



Source: Company data, Bloomberg, CMBIGM estimates

Figure 4: 12M trailing P/B band



Source: Company data, Bloomberg, CMBIGM estimates



Financial Summary

INCOME STATEMENT	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Revenue	27,760	30,167	32,172	35,702	38,307	40,985
Cost of goods sold	(16,541)	(19,091)	(20,318)	(22,286)	(23,539)	(24,807)
Gross profit	9,000	8,757	9,463	10,763	11,922	13,133
Operating expenses	(8,903)	(8,139)	(8,064)	(8,722)	(9,359)	(10,013)
Selling expense	(4,985)	(4,097)	(4,200)	(4,641)	(4,980)	(5,328)
Admin expense	(1,700)	(1,723)	(1,473)	(1,428)	(1,532)	(1,639)
Others	(2,219)	(2,319)	(2,391)	(2,653)	(2,847)	(3,046)
EBITDA	3,459	4,044	4,872	5,785	6,601	7,456
Depreciation	(899)	(900)	(889)	(929)	(1,022)	(1,114)
Other amortisation	(244)	(208)	(193)	(163)	(170)	(177)
EBIT	2,316	2,937	3,790	4,693	5,410	6,165
Other income/expense	3,240	4,479	5,006	5,924	6,641	7,396
Pre-tax profit	3,240	4,479	5,006	5,924	6,641	7,396
Income tax	(913)	(1,223)	(1,201)	(1,422)	(1,594)	(1,775)
Minority interest	(126)	(101)	(94)	(111)	(125)	(139)
Net profit	2,201	3,155	3,711	4,391	4,922	5,482
Gross dividends	1,023	1,501	2,456	2,906	3,257	3,628
	1,020	1,001	_, .00	_,000	3,201	0,020
BALANCE SHEET	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Current assets	24,628	28,959	32,002	32,781	33,625	34,794
Cash & equivalents	18,467	14,598	17,855	18,218	18,796	19,696
Account receivables	125	125	120	133	142	152
Inventories	3,281	3,493	4,152	4,554	4,810	5,070
Prepayment	314	903	965	965	965	965
Other current assets	2,441	9,840	8,911	8,911	8,911	8,911
Non-current assets	16,886	17,604	18,309	20,061	21,584	23,007
PP&E	10,302	10,148	11,009	12,524	13,817	15,018
Deferred income tax	1,718	2,131	2,250	2,250	2,250	2,250
Investment in JVs & assos	374	366	368	538	708	878
Intangibles	2,501	2,481	2,558	2,625	2,684	2,737
Goodwill	1,307	1,307	1,307	1,307	1,307	1,307
Other non-current assets	684	1,171	817	817	817	817
Total assets	41,514	46,563	50,312	52,842	55,209	57,801
	,-	,	,-	- ,-		, , , , ,
Current liabilities	15,510	18,259	19,672	20,027	20,252	20,481
Short-term borrowings	703	246	225	225	225	225
Account payables	2,372	3,298	3,662	4,017	4,242	4,471
Other current liabilities	12,435	14,715	15,785	15,785	15,785	15,785
Non-current liabilities	4,636	4,511	4,368	4,496	4,496	4,496
Long-term borrowings	0	0	0	0	0	0
Other non-current liabilities	4,636	4,511	4,368	4,496	4,496	4,496
Total liabilities	20,146	22,769	24,039	24,523	24,749	24,977
Share capital	1,364	1,364	1,364	1,364	1,364	1,364
Capital surplus	5,076	5,357	5,555	5,555	5,555	5,555
Retained earnings	14,481	16,319	18,528	20,464	22,480	24,705
Other reserves	(299)	(38)	47	47	47	47
Total shareholders equity	20,622	23,002	25,495	27,430	29,447	31,671
Minority interest	746	792	777	889	1,014	1,153
Total equity and liabilities	41,514	46,563	50,312	52,842	55,209	57,801
· · · · · · · · · · · · · · · · · · ·	,	,	,	,	,=	3.,001



CASH FLOW	2020A	2021A	2022A	2023E	2024E	2025E
'E 31 Dec (RMB mn)						
perating						
rofit before taxation	3,240	4,479	5,006	5,924	6,641	7,39
Depreciation & amortization	1,143	1,108	1,082	1,092	1,192	1,29
ax paid	(913)	(1,223)	(1,201)	(1,422)	(1,594)	(1,775
hange in working capital	525	120	(27)	(61)	(40)	(41
Others	958	1,559	19	0	0	(
let cash from operations	4,953	6,043	4,879	5,534	6,199	6,87
vesting						
Capital expenditure	(1,460)	(1,359)	(2,545)	(2,545)	(2,545)	(2,545
cquisition of subsidiaries/ investments	(3,000)	(22,990)	(17,259)	0	0	(
Others	2,973	14,100	17,604	(170)	(170)	(170
et cash from investing	(1,488)	(10,250)	(2,199)	(2,715)	(2,715)	(2,715
inancing						
ividend paid	(793)	(1,111)	(1,576)	(2,456)	(2,906)	(3,257
roceeds from share issues	244	6	0	0	0	(
Others	193	(509)	(99)	0	0	(
let cash from financing	(356)	(1,614)	(1,676)	(2,456)	(2,906)	(3,257
let change in cash						
Cash at the beginning of the year	14,557	17,643	11,814	12,840	13,203	13,78
xchange difference	(24)	(9)	22	0	0	(
Others	824	2,784	5,015	5,015	5,015	5,01
ash at the end of the year	18,467	14,598	17,855	18,218	18,796	19,69
ROWTH	2020A	2021A	2022A	2023E	2024E	2025E
E 31 Dec						
Revenue	(0.8%)	8.7%	6.6%	11.0%	7.3%	7.0%
Gross profit	4.8%	(2.7%)	8.1%	13.7%	10.8%	10.29
BITDA	27.8%	16.9%	20.5%	18.7%	14.1%	13.09
BIT	46.2%	26.8%	29.1%	23.8%	15.3%	14.09
let profit	18.9%	43.3%	17.6%	18.3%	12.1%	11.49
PROFITABILITY	2020A	2021A	2022A	2023E	2024E	2025E
E 31 Dec						
Gross profit margin	32.4%	29.0%	29.4%	30.1%	31.1%	32.09
BITDA margin	12.5%	13.4%	15.1%	16.2%	17.2%	18.29
eturn on equity (ROE)	11.1%	14.5%	15.3%	16.6%	17.3%	17.9%
SEARING/LIQUIDITY/ACTIVITIES	2020A	2021A	2022A	2023E	2024E	2025E
E 31 Dec						
let debt to equity (x)	(0.9)	(0.6)	(0.7)	(0.7)	(0.6)	(0.6
current ratio (x)	1.6	1.6	1.6	1.6	1.7	1.
eceivable turnover days	1.6	1.5	1.4	1.4	1.4	1.
ventory turnover days	72.4	66.8	74.6	74.6	74.6	74.
ayable turnover days	52.3	63.1	65.8	65.8	65.8	65.
ALUATION	2020A	2021A	2022A	2023E	2024E	2025E
E 31 Dec						
//E	31.3	25.4	22.0	19.3	17.2	15.
/E (diluted)	31.3	25.5	22.1	19.3	17.2	15.
//B	3.3	3.5	3.2	3.1	2.9	2.
iv yield (%)	1.5	1.9	3.0	3.4	3.9	4.

PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (l)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.